What is ARS Pharmaceuticals, Inc.'s long-term debt?

ARS Pharmaceuticals, Inc. (SPRY) reported long-term debt of $96.52M in Q1 2026.

What is the long-term trend for ARS Pharmaceuticals, Inc.'s long-term debt?

Over 3 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s long-term debt has grown at a 169.4% compound annual growth rate (CAGR), from $4.93M to $96.37M.

What does long-term debt mean?

Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

ARS Pharmaceuticals, Inc. SPRY Long-Term Debt

Long-Term Debt at other companies

Amneal Pharmaceuticals, Inc.AMRX

$2.57B+19.1%

ViatrisVTRS

$12.41B-12.4%

AMP

Amphastar PharmaceuticalsAMPH

$609.8M+1.0%

Eton Pharmaceuticals, Inc.ETON

$18.94M-36.9%

Other financials

Income statement

See full

Revenue$22.7M+184%

Operating income-$60.1M-61.8%

Net income-$60.6M-78.6%

EPS (diluted)-$0.61-74.3%

Balance sheet

See full

Cash & equivalents$24.3M-39.0%

Total debt$96.5M+132,122%

Total equity$61.3M-73.2%

Total assets$287.6M-12.1%

Cash flow

See full

Operating cash flow-$44.9M-10.3%

CapEx--100%

Free cash flow-$44.9M-10.1%

Valuation

See full

Market cap$1.05B-32.6%

Enterprise value$1.12B-26.0%

P/S10.6×-5.4×

Profitability

See full

Operating margin-204.5%—

Net margin-200%-219pp

FCF margin-177.1%-206pp

Returns & leverage

See full

Return on equity-136.4%-144pp

Debt / equity1.6×+1.6×

Current ratio4.9×-6.1×

Where this comes from

Reported directly by ARS Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about ARS Pharmaceuticals, Inc.'s long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s long-term debt?: ARS Pharmaceuticals, Inc. (SPRY) reported long-term debt of $96.52M in Q1 2026.
What is the long-term trend for ARS Pharmaceuticals, Inc.'s long-term debt?: Over 3 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s long-term debt has grown at a 169.4% compound annual growth rate (CAGR), from $4.93M to $96.37M.
What does long-term debt mean?: Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.